New considerations for Haemophilus influenzae type b vaccination

Area of Science:

• Pediatrics
• Immunology
• Vaccinology

Background:

• Three Haemophilus influenzae type b (Hib) conjugate vaccines are available: ProHIBiT, HibTITER, and PedvaxHIB.
• HibTITER and PedvaxHIB are approved for infants from two months of age, while ProHIBiT is licensed for children 15 months and older.

Purpose of the Study:

• To compare the immunogenicity, efficacy, adverse effects, dosage, and cost of three commercially available Haemophilus influenzae type b (Hib) conjugate vaccines.
• To provide guidance on the selection of appropriate Hib vaccines for infants.

Main Methods:

• Comparative analysis of published data on Hib conjugate vaccines.
• Review of recommendations from the Centers for Disease Control Immunization Practices Advisory Committee (ACIP) and the American Academy of Pediatrics (AAP).

Main Results:

• HibTITER and PedvaxHIB demonstrate efficacy in infants from two months, whereas ProHIBiT does not provide adequate protection in this age group.
• The three vaccines elicit different immunologic responses and are not interchangeable; dosage schedules vary.
• Full immunization with HibTITER is more costly due to the required four-dose series.

Conclusions:

• HibTITER and PedvaxHIB are recommended for infant immunization against Haemophilus influenzae type b (Hib) disease, starting at two months of age.
• Vaccine selection should consider availability, cost, and clinical judgment based on existing data.
• The Centers for Disease Control Immunization Practices Advisory Committee (ACIP) and the American Academy of Pediatrics (AAP) endorse HibTITER or PedvaxHIB for routine infant immunization.